Immunotherapy drug fails in brain tumour treatment trial

Organisation: Position: Deadline Date: Location:

Bristol-Myers Squibb Co has announced that its immunotherapy drug Opdivo has failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumour that affects the brain or the spine, reports Reuters Health.

Opdivo, used in combination with radiation therapy, failed to extend survival in patients with glioblastoma multiforme (GBM), when compared with the chemotherapy temozolomide and radiation therapy.

The report says GBM is the most common type of tumour that forms in the nervous system. The standard treatment involves surgery, along with radiation therapy and chemotherapy.

Opdivo is Bristol’s growth driver and brought in $1.8bn in first-quarter sales.

The report says the drug is already approved as a treatment for types of skin, lung and kidney cancers, and faces fierce competition for other immunotherapies including those from rivals Merck & Co Inc and Roche Holding.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.